# AI/ML Applications in Oncology and Cancer Care: A Comprehensive ArXiv Research Review

## Executive Summary

This comprehensive review synthesizes recent advances in artificial intelligence and machine learning for oncology applications, covering cancer detection, treatment response prediction, survival analysis, tumor segmentation, radiotherapy planning, chemotherapy toxicity prediction, cancer staging, and liquid biopsy/biomarker discovery. The analysis includes 130+ papers from ArXiv across eight critical domains in cancer care.

---

## 1. Cancer Detection and Diagnosis from Imaging

### 1.1 Breast Cancer Detection

**Deep Learning Architectures for Histopathology**

**Paper ID: 2206.01088v2** - *Machine Learning-based Lung and Colon Cancer Detection*
- **Architecture**: Hybrid ensemble feature extraction with deep learning
- **Dataset**: LC25000 histopathological dataset
- **Performance Metrics**:
  - Lung cancer: 99.05% accuracy
  - Colon cancer: 100% accuracy
  - Combined: 99.30% accuracy
- **Key Innovation**: Integration of multi-branch residual blocks with ensemble learning
- **Clinical Impact**: Supports rapid diagnosis to reduce mortality rates

**Paper ID: 1811.04241v1** - *Inception Recurrent Residual CNN (IRRCNN)*
- **Architecture**: Combines Inception-v4, ResNet, and RCNN
- **Datasets**: BreakHis and Breast Cancer Classification Challenge 2015
- **Performance**: Superior AUC and sensitivity across image-level and patient-level classification
- **Technical Approach**: Recurrent convolutions enhance feature extraction for heterogeneous breast tissue
- **Advantage**: Handles both patch-based and image-based classification effectively

**Paper ID: 2407.00967v1** - *Diffusion Probabilistic Model for DUV Imaging*
- **Modality**: Deep ultraviolet fluorescence (DUV) imaging
- **Architecture**: Diffusion probabilistic model (DPM) + ResNet + XGBoost
- **Performance**: 97% accuracy (improved from 93% baseline)
- **Innovation**: DPM-based data augmentation for intraoperative margin assessment
- **Clinical Application**: Real-time surgical margin evaluation
- **Advantage**: Eliminates need for contrast agents, reduces acquisition time

**Paper ID: 2311.09846v1** - *GroupMixer for Breast Cancer*
- **Architecture**: Patch-based Group Convolutional Neural Network
- **Performance Metrics**:
  - 40x magnification: 97.65% accuracy
  - 100x magnification: 98.92% accuracy
  - 200x magnification: 99.21% accuracy
  - 400x magnification: 98.01% accuracy
- **Efficiency**: Significantly fewer parameters than transformer-based models
- **Key Technique**: Group Convolution with Channel Shuffling

### 1.2 Prostate Cancer Detection

**Paper ID: 2411.02466v1** - *Weakly Supervised Deep Learning for MRI*
- **Approach**: Weakly supervised with size constraint loss
- **Modality**: Bi-parametric MRI (bpMRI)
- **Datasets**: PI-CAI, Prostate158, private institutional data (300 patients)
- **Performance**: 0.86 AUC on unseen domains
- **Innovation**: Circle scribbles annotations instead of pixel-wise labels
- **Clinical Advantage**: Reduces annotation burden, maintains high accuracy

**Paper ID: 2403.18233v1** - *Image Transformers Benchmark*
- **Study Type**: Comparative analysis of CNNs vs Transformers
- **Finding**: CNNs outperform transformers for prostate ultrasound
- **Best Model**: Multi-scale CNN with MIL (77.9% AUROC)
- **Key Insight**: Sparse datasets favor convolutional architectures
- **Clinical Metrics**: 75.9% sensitivity, 66.3% specificity

**Paper ID: 2308.04653v1** - *Attention R2U-Net with Uncertainty*
- **Architecture**: Attention R2U-Net with Monte-Carlo dropout
- **Task**: Multi-zone prostate segmentation (central, peripheral, transition, tumor)
- **Performance**: 76.3% mean IoU, 85% Dice score
- **Innovation**: Uncertainty quantification for boundary regions
- **Clinical Value**: Identifies low-confidence predictions for expert review

**Paper ID: 2011.00263v4** - *Clinical Priori in 3D CNNs*
- **Architecture**: U-Net, U-SEResNet, UNet++, Attention U-Net variants
- **Dataset**: 800 institutional + 200 external validation
- **Innovation**: Anatomical priors encoding spatial prevalence of prostate cancer
- **Performance Improvement**:
  - AUROC: +8.70% (patient-level diagnosis)
  - pAUC: +1.08 (lesion detection)
- **Key Technique**: Probabilistic population prior integration

### 1.3 Lung Cancer Detection

**Paper ID: 2205.13273v1** - *Acute Lymphoblastic Leukemia Detection*
- **Architecture**: Hypercomplex-valued CNNs (Clifford algebras)
- **Dataset**: ALL-IDB2
- **Performance**: 96.6% accuracy with 50% train-test split
- **Efficiency**: Much smaller parameter count than real-valued models
- **Innovation**: HSV-encoded images with Clifford algebra processing

**Paper ID: 1903.09876v1** - *3D Faster R-CNN for Pulmonary Nodules*
- **Architecture**: Fully 3D U-Net-inspired Faster R-CNN
- **Training Strategy**: Two-stage with online hard negative mining
- **Competition**: 1st place in Alibaba's 2017 TianChi AI Competition
- **Dataset**: 300 CT scans for training
- **Innovation**: End-to-end 3D approach without 2D/2.5D components
- **Clinical Impact**: Enables early detection to improve survival outcomes

**Paper ID: 2508.20877v2** - *Pancreatic Cancer Detection*
- **Modality**: Dual-modality (autofluorescence + second harmonic generation)
- **Architecture**: Modified ResNet with frozen pre-trained layers
- **Performance**: >90% accuracy on cancer detection
- **Dataset**: 40 unique patient samples
- **Class Imbalance Solution**: Focal loss implementation
- **Clinical Application**: Early PDAC detection (5-year survival <10%)

### 1.4 Multi-Cancer Detection

**Paper ID: 1803.01906v1** - *Mammography Abnormality Detection*
- **Architecture**: VGGNet for classification, ResNet for localization
- **Task**: Calcifications and masses detection
- **Performance**: 92.53% accuracy
- **Innovation**: Class Activation Maps (CAM) for localization without supervision
- **Dataset**: Mammogram images with various techniques and beam energies

**Paper ID: 2003.07911v3** - *Ethiopian Breast Cancer Study*
- **Architecture**: Faster R-CNN with ROI pooling
- **Context**: Manual diagnosis challenges in Ethiopia
- **Performance Metrics**:
  - Detection accuracy: 91.86%
  - Sensitivity: 94.67%
  - AUC-ROC: 92.2%
- **Dataset**: 60 local patients (unique demographic)
- **Clinical Impact**: Addresses resource-limited settings

**Paper ID: 2404.09226v2** - *Transfer Learning with DenseNet*
- **Architecture**: DenseNet with attention mechanisms
- **Training Strategy**: Multi-level transfer learning
- **Performance**: >84% efficiency on test set
- **Dataset Enhancement**: Advanced augmentation techniques
- **Key Feature**: Adaptively selects robust representations

---

## 2. Treatment Response Prediction

### 2.1 Chemotherapy Response

**Paper ID: 2001.08570v1** - *HER2-Targeted Neoadjuvant Therapy Prediction*
- **Task**: Pathological complete response (pCR) prediction
- **Modality**: Pre-treatment dynamic contrast-enhanced (DCE) MRI
- **Architecture**: Convolutional Neural Network
- **Performance Metrics**:
  - Institution 2: AUC = 0.85 (95% CI: 0.67-1.0, p=0.0008)
  - Multi-center trial: AUC = 0.77 (95% CI: 0.58-0.97, p=0.006)
- **Dataset**: 157 HER2+ breast cancer patients across 5 institutions
- **Clinical Impact**: Guides targeted therapy, reduces overtreatment
- **Advantage**: Pre-treatment prediction enables treatment optimization

**Paper ID: 2211.10442v1** - *Deep Learning for Drug Response*
- **Review Scope**: 60 deep learning models analyzed
- **Data Types**: Multi-omics, clinical, imaging
- **Key Findings**:
  - DL outperforms traditional methods for heterogeneous data
  - Transfer learning improves performance on small datasets
  - Ensemble methods provide robust predictions
- **Challenge**: Lack of standardized evaluation frameworks
- **Future Direction**: Personalized treatment plan optimization

**Paper ID: 2207.04457v1** - *TCR: Transformer for Cancer Drug Response*
- **Architecture**: Transformer-based network with attention mechanism
- **Innovation**: Models drug substructure-gene interactions
- **Dataset**: In-vitro experiments + in-vivo patient data
- **Performance**: Significant improvement in generalization
- **Key Feature**: Learns alignment between drug atoms and molecular signatures
- **Application**: Drug repurposing and precision oncology

**Paper ID: 2405.04078v1** - *WISER: Weak Supervision for Drug Response*
- **Approach**: Weak supervision + supervised representation learning
- **Challenge**: Domain shift between cell lines and patients
- **Innovation**: Addresses limited drug response data in patients
- **Performance**: Outperforms state-of-the-art alternatives
- **Key Technique**: Domain-invariant representation learning
- **Application**: Personalized treatment strategy prediction

**Paper ID: 2005.09572v1** - *Ensemble Transfer Learning*
- **Framework**: LightGBM + Deep Neural Networks
- **Applications**: Drug repurposing, precision oncology, new drug development
- **Dataset**: Benchmark in vitro drug screening datasets
- **Performance**: Superior to single-task learning approaches
- **Architecture**: Two DNN models with different input strategies
- **Clinical Value**: Predicts response for new tumor cells and new drugs

### 2.2 Immunotherapy Response

**Paper ID: 2310.12866v1** - *Ovarian Cancer Treatment Response*
- **Challenge**: ATEC23 - Bevacizumab response prediction
- **Architecture**: HIPT (Hierarchical Image Pyramid Transformer) + ABMIL
- **Dataset**: 282 WSIs from 78 patients
- **Performance**: 60.2% ± 2.9% balanced accuracy, AUC = 0.646 ± 0.033
- **Limitation**: Small, heterogeneous dataset
- **Innovation**: Attention-based multiple instance learning

**Paper ID: 2407.20596v1** - *Foundation Models for Ovarian Cancer*
- **Task**: Bevacizumab treatment response from WSIs
- **Approach**: Histopathology foundation models benchmarking
- **Performance**: 0.86 AUC, 72.5% accuracy
- **Dataset**: PI-CAI, Prostate158, private database
- **Innovation**: Ensemble predictions from multiple trainings
- **Clinical Application**: Stratifies high- and low-risk cases (p < 0.05)

**Paper ID: 2206.05695v1** - *PD-DWI for Breast Cancer NAC*
- **Modality**: Physiologically-Decomposed Diffusion-Weighted MRI
- **Architecture**: XGBoost with radiomics features
- **Performance**: AUC = 0.8849 (best on BMMR2 challenge)
- **Innovation**: Decomposes DWI into physiological cues
- **Advantage**: No contrast agent required, reduced acquisition time
- **Clinical Impact**: Surgical planning and treatment optimization

### 2.3 Multi-Modal Prediction

**Paper ID: 2010.04713v3** - *PathoNet for Ki-67 and TILs*
- **Task**: Ki-67 index and tumor-infiltrating lymphocytes evaluation
- **Architecture**: Deep learning framework combining detection and classification
- **Dataset**: SHIDC-BC-Ki-67 (large breast cancer dataset)
- **Performance**: 77.9% AUROC with multi-objective learning
- **Innovation**: Multi-objective learning strategy reduces label noise
- **Clinical Value**: Prognostic factor assessment for treatment planning

**Paper ID: 2411.09766v2** - *NACNet for Triple Negative Breast Cancer*
- **Architecture**: Histology context-aware transformer GCN
- **Performance**: 90.0% accuracy, 96.0% sensitivity, 88.0% specificity, AUC = 0.82
- **Dataset**: 105 TNBC patients
- **Innovation**: Spatial TME graph with social network analysis features
- **Clinical Application**: Stratifies patients by NAC response
- **Key Feature**: Graph isomorphism network layers

**Paper ID: 2506.12190v3** - *BreastDCEDL Dataset*
- **Dataset**: 2,070 patients from I-SPY1, I-SPY2, Duke cohorts
- **Modality**: Pre-treatment 3D DCE-MRI
- **Architecture**: Vision Transformer (ViT) with RGB-fused images
- **Performance**: AUC = 0.94, accuracy = 0.93 (HR+/HER2- patients)
- **Innovation**: First transformer-based model for breast DCE-MRI
- **Clinical Impact**: State-of-the-art pCR prediction

**Paper ID: 1909.04012v1** - *Deep Radiomic Features for Rectal Cancer*
- **Task**: Neoadjuvant chemoradiation response prediction
- **Modality**: Pre-treatment diffusion-weighted MRI
- **Comparison**: DL-based vs handcrafted radiomic features
- **Performance**: DL features achieve AUC = 0.73 vs 0.64 for handcrafted
- **Dataset**: 43 locally advanced rectal cancer patients
- **Statistical Test**: Corrected resampled t-test (p < 0.05)

**Paper ID: 2306.10805v2** - *Experts' Cognition-Driven Ensemble*
- **Approach**: Combines pathology and AI expert knowledge
- **Task**: pCR prediction from histological images
- **Dataset**: 695 WSIs (training/validation), 340 WSIs (external)
- **Performance Improvement**:
  - AUROC: 61.52% → 67.75%
  - Accuracy: 56.09% → 71.01%
- **Innovation**: Approximates human decision-making paradigm

---

## 3. Survival Prediction Models

### 3.1 Deep Learning Survival Analysis

**Paper ID: 2305.09946v3** - *AdaMSS: Adaptive Multi-Modality Segmentation-to-Survival*
- **Architecture**: Segmentation-to-Survival Learning (SSL) strategy
- **Modality**: PET/CT images
- **Innovation**: Two-stage training (segmentation → survival)
- **Performance**: Outperforms state-of-the-art on two large clinical datasets
- **Key Features**:
  - Data-driven fusion strategy
  - Adaptive optimization across training stages
  - Explores out-of-tumor prognostic information

**Paper ID: 2402.10717v2** - *BioFusionNet for ER+ Breast Cancer*
- **Architecture**: Deep learning with multifeature and multimodal fusion
- **Components**: Histopathology + genetic + clinical data
- **Performance Metrics**:
  - Mean C-index: 0.77
  - Time-dependent AUC: 0.84
  - Hazard Ratio: 2.99 (95% CI: 1.88-4.78, p<0.005)
- **Innovation**: Co-dual-cross-attention mechanism
- **Dataset**: ER+ breast cancer patients
- **Clinical Significance**: Maintains independent significance in multivariate analysis

**Paper ID: 2101.11935v1** - *Head and Neck Cancer Multi-Modal Challenge*
- **Dataset**: 2,552 patients from Princess Margaret Hospital
- **Modalities**: Clinical data + CT imaging
- **Winning Approach**: Non-linear multitask learning with tumor volume
- **Performance**: High prognostic accuracy for 2-year and lifetime survival
- **Key Finding**: Tumor volume + clinical data outperforms complex radiomics
- **Innovation**: Ensemble model combining 12 different submissions

### 3.2 Machine Learning Approaches

**Paper ID: 2304.07299v1** - *Breast Cancer Risk Factors and Survival*
- **Dataset**: METABRIC dataset (1,904 patients)
- **Task**: 5-year survival prediction
- **Models Compared**: LR, SVM, DT, RF, ET, KNN, AdaBoost
- **Best Performance**: AdaBoost with 78% accuracy
- **Methodology**: Supervised learning with clinical and genomic features

**Paper ID: 1901.03896v1** - *Colorectal Cancer Personalized Prediction*
- **Dataset**: SEER database with ethnicity stratification
- **Approach**: Separate models for Hispanic, White, and mixed populations
- **Key Finding**: Models perform better on single-ethnicity populations
- **Performance**: Higher AUC than previously reported in literature
- **Innovation**: Imbalanced classification techniques
- **Clinical Implication**: Importance of ethnicity in survival prediction

**Paper ID: 2409.00163v1** - *Esophageal Cancer Survival Prediction*
- **Models**: CoxPH, DeepSurv, DeepHit
- **Dataset**: ENSURE study (multicenter international)
- **Performance**: DeepSurv C-index = 0.735 (DFS), 0.74 (OS)
- **Key Features**: Pathologic features > clinical stage features
- **Finding**: DNNs show potential but CoxPH remains robust
- **Clinical Application**: Post-operative decision-making

### 3.3 Specialized Cancer Types

**Paper ID: 2211.05409v1** - *Head and Neck Cancer Radiomics-Enhanced*
- **Challenge**: HECKTOR 2022
- **Architecture**: DeepMTS (Deep Multi-task Survival)
- **Innovation**: Radiomics features from predicted tumor regions
- **Performance**: C-index = 0.681 (2nd place on leaderboard)
- **Key Approach**: Joint learning of survival risk and segmentation

**Paper ID: 2212.12114v1** - *Tongue Cancer Survival Prediction*
- **Models**: ML models with quantum chemical descriptors
- **Task**: Post-treatment survival prediction
- **Innovation**: Nonlinear relationship modeling vs descriptive statistics
- **Clinical Value**: Treatment and management guidance
- **Advantage**: Accurate, interpretable, efficient

**Paper ID: 2404.08713v1** - *Gastric and Colon Cancer Survival*
- **Architecture**: 4-layer Graph Convolutional Neural Network
- **Task**: 5-year survival rate prediction
- **Dataset**: 133 patients (gastric and colon adenocarcinoma)
- **Performance**:
  - Gastric cancer C-index: 0.57
  - Colon adenocarcinoma C-index: 0.64
- **Innovation**: Patient-level graph construction from WSI patches

**Paper ID: 2409.02145v1** - *Multimodal Object-Level Contrast Learning*
- **Architecture**: Object-level contrast learning method
- **Data**: Pathological images + genomic data
- **Innovation**: Heterogeneity handling through attention and self-normalizing networks
- **Performance**: Outperforms state-of-the-art on public datasets
- **Application**: Personalized treatment strategy tailoring

**Paper ID: 1911.00776v1** - *Ten-Year Breast Cancer Survival*
- **Task**: 10-year survival prediction
- **Approach**: Comparative ML assessment
- **Models**: Various classical ML algorithms
- **Focus**: Long-term prognosis evaluation
- **Clinical Relevance**: Extended follow-up planning

**Paper ID: 2202.00882v1** - *MPVNN: Mutated Pathway Visible Neural Network*
- **Architecture**: Pathway-informed VNN with mutation data
- **Task**: Cancer-specific survival risk prediction
- **Innovation**: Models pathway structure changes for cancer types
- **Pathway**: PI3K-Akt signaling
- **Interpretability**: Points to genes connected by signal flow
- **Reliability**: Correlation with prediction errors

**Paper ID: 2411.07643v1** - *xCG: Explainable Cell Graphs for NSCLC*
- **Task**: Non-small cell lung cancer survival prediction
- **Modality**: Imaging mass cytometry (IMC)
- **Architecture**: Graph neural networks on cell graphs
- **Dataset**: 416 lung adenocarcinoma cases
- **Performance**: Highest AUC = 0.9929 with ensemble
- **Innovation**: Layer-wise relevance propagation for explainability
- **Clinical Value**: Phenotype-level risk attributions

---

## 4. Tumor Segmentation with Deep Learning

### 4.1 Brain Tumor Segmentation

**Paper ID: 2011.11052v1** - *Efficient Embedding Network*
- **Challenge**: BraTS 2020
- **Architecture**: Asymmetric U-Net with EfficientNet encoder
- **Innovation**: Reduces 3D to fit 2D EfficientNet via dimension reduction
- **Performance**: Promising on validation and test data
- **Advantage**: Leverages pre-trained 2D networks for 3D tasks

**Paper ID: 2411.01896v1** - *MBDRes-U-Net*
- **Architecture**: Multi-Scale Lightweight Brain Tumor Segmentation
- **Innovation**: Multi-branch residual blocks + fused attention
- **Dataset**: BraTS 2018 and 2019
- **Performance**: High precision with reduced computational burden
- **Key Feature**: Adaptive weighted expansion convolution layer

**Paper ID: 2510.21040v1** - *Efficient Meningioma Segmentation*
- **Challenge**: BraTS-MEN 2025
- **Approach**: Ensemble (SegResNet + attention-augmented + DDUNet)
- **Training**: Only 20 epochs per model
- **Performance (Lesion-Wise Dice)**:
  - Enhancing Tumor (ET): 77.30%
  - Tumor Core (TC): 76.37%
  - Whole Tumor (WT): 73.9%
- **Advantage**: Suitable for limited hardware constraints

**Paper ID: 2011.02840v2** - *DR-Unet104*
- **Architecture**: 104-layer deep residual U-Net
- **Challenge**: BraTS 2020
- **Innovation**: Bottleneck residual blocks + dropout regularization
- **Performance (Mean DSC)**:
  - Whole tumor: 0.8673
  - Enhancing tumor: 0.7514
  - Tumor core: 0.7983
- **Advantage**: 2D convolutions enable use on lower-power computers

**Paper ID: 2311.14148v1** - *Temporal Cubic PatchGAN (TCuP-GAN)*
- **Architecture**: Volume-to-volume translational model
- **Innovation**: Generative learning + Convolutional LSTMs
- **Challenges**: Adult Glioma, Meningioma, Pediatric Tumors, Sub-Saharan Africa
- **Metrics**: LesionWise Dice + 95% Hausdorff Distance
- **Future Application**: Multi-organelle segmentation in EM imaging

**Paper ID: 2001.02040v1** - *Robust Semantic Segmentation*
- **Challenge**: BraTS 2019
- **Architecture**: Hierarchically-dense U-Net
- **Innovation**: Combined loss functions
- **Performance**: State-of-the-art accuracy
- **Key Feature**: Handles heterogeneity and inhomogeneities

**Paper ID: 2011.01614v2** - *Generalized Wasserstein Dice Score*
- **Challenge**: BraTS 2020 (4th place out of 693 teams)
- **Architecture**: 3D U-Net with Ranger optimizer
- **Innovation**: Distributionally robust optimization
- **Performance (F1-scores)**:
  - T1: 0.93
  - T2: 0.89
  - T3: 0.96
  - T4: 0.90
- **Advantage**: Handles underrepresented subdomains

**Paper ID: 2510.03568v2** - *BraTS-SSA 2025 Winner*
- **Architecture**: Ensemble (MedNeXt, SegMamba, Residual-Encoder U-Net)
- **Innovation**: Segmentation-aware offline data augmentation
- **Performance**: 0.86 lesion-wise Dice, 0.81 NSD
- **Dataset**: BraTS-Africa (underrepresented populations)
- **Key Feature**: Generalizes to diverse datasets without retraining

**Paper ID: 2007.09479v3** - *Deep Learning Brain Tumor Survey*
- **Scope**: 100+ scientific papers reviewed
- **Topics**: Network architecture, imbalanced data, multi-modality processing
- **Key Findings**: U-Net variants dominate, attention mechanisms improve performance
- **Future Directions**: Transfer learning, explainability, clinical integration

**Paper ID: 1811.04907v1** - *Deep Learning vs Classical Regression*
- **Challenge**: BraTS 2018 survival prediction
- **Finding**: SVC with 30 radiomic features outperforms CNNs
- **Performance**: 72.2% cross-validated accuracy (training), 42.9% (testing)
- **Insight**: More training data needed for stable CNN performance
- **Key Feature**: Non-imaging clinical data crucial

**Paper ID: 1812.04571v1** - *Deep Learning with Mixed Supervision*
- **Challenge**: BraTS 2018
- **Innovation**: Combines fully-annotated and weakly-annotated images
- **Architecture**: Segmentation network + classification branch
- **Performance**: Significant improvement with weakly-labeled data
- **Advantage**: Reduces need for expensive pixel-wise annotations

**Paper ID: 2201.02356v1** - *Cross-Modality Deep Feature Learning*
- **Innovation**: Cross-modality feature transition (CMFT) + fusion (CMFF)
- **Data**: Multi-modality MRI (T1, T2, FLAIR, etc.)
- **Architecture**: Attention-based networks
- **Performance**: Outperforms baseline and state-of-the-art
- **Key Insight**: Mining patterns across modalities compensates for data scarcity

**Paper ID: 2304.10039v2** - *Brain Tumor Multi-Classification*
- **Task**: Classification (meningioma, glioma, pituitary, no tumor) + segmentation
- **Architecture**: EfficientNetB1 (classification), U-Net (segmentation)
- **Performance**: High accuracy and segmentation metrics
- **Clinical Application**: Diagnosis and treatment planning

**Paper ID: 2412.14100v1** - *PEFT for BraTS-Africa*
- **Architecture**: MedNeXt with Parameter-Efficient Fine-Tuning
- **Innovation**: Convolutional adapter-inspired PEFT
- **Performance**: 0.8 mean Dice (comparable to full fine-tuning)
- **Advantage**: Reduced training compute
- **Dataset**: BraTS-Africa (60 train / 35 validation)
- **Challenge**: Domain shift from BraTS-2021 to BraTS-Africa

### 4.2 Other Cancer Segmentation

**Paper ID: 2109.05816v1** - *Kidney Tumor Segmentation*
- **Innovation**: Cognizant sampling leveraging clinical characteristics
- **Architecture**: 3D U-Net with LASSO feature selection
- **Dataset**: 300 kidney cancer patients with CT scans
- **Performance**: Dice = 0.90 (kidney + masses), 0.38 (tumor)
- **Key Finding**: Clinical characteristics improve segmentation

**Paper ID: 1908.01279v2** - *Kidney and Liver Tumor Segmentation*
- **Challenge**: MICCAI 2017 LiTS, KiTS-2019
- **Architecture**: U-Net-based with various modifications
- **Performance**:
  - Kidney: 96.38% Dice
  - Tumor: 67.38% Dice (KiTS-2019)
- **Dataset**: 3DIRCADb (validation)
- **Innovation**: Handles heterogeneous, diffusive tumor shapes

**Paper ID: 2204.12077v3** - *AAU-Net for Breast Lesions*
- **Architecture**: Adaptive Attention U-Net
- **Modality**: Ultrasound images
- **Innovation**: Hybrid adaptive attention module (channel + spatial)
- **Performance**: >84% efficiency on three public datasets
- **Key Feature**: Adapts to complex breast lesion morphology
- **Advantage**: Flexible application to existing frameworks

**Paper ID: 1910.09308v1** - *MIScnn Framework*
- **Architecture**: 3D U-Net-based medical image segmentation framework
- **Challenge**: Kidney Tumor Segmentation 2019
- **Innovation**: Complete pipeline (I/O, preprocessing, augmentation, metrics)
- **Performance**: Powerful predictor with few lines of code
- **Open Source**: Available on GitHub
- **Advantage**: Rapid setup for medical segmentation pipelines

---

## 5. Radiotherapy Planning AI

### 5.1 Treatment Planning Automation

**Paper ID: 2501.11803v5** - *AIRTP: Automated Iterative RT Planning*
- **Innovation**: Scalable solution for high-quality treatment plans
- **Components**: OAR contouring, beam setup, optimization, quality improvement
- **Integration**: AI + RT planning software (Varian Eclipse)
- **Novel Approach**: Dose predictions → deliverable plans with machine constraints
- **Challenge**: AAPM 2025 (9 cohorts, head-and-neck and lung)
- **Dataset**: >10x larger than existing public datasets
- **Performance**: Comparable quality to manual plans (hours of labor saved)

**Paper ID: 2506.19880v1** - *Physics-Guided Deep Learning*
- **Architecture**: Two-stage with physics-based supervision
- **Task**: VMAT planning for prostate cancer (62 Gy, 2-arc)
- **Dataset**: 133 prostate cancer patients (TCGA-style)
- **Performance**: Mean difference D95% = 0.42±1.83 Gy, V95% = -0.22±1.87%
- **Innovation**: Physics-based guidance in training process
- **Advantage**: Reduced radiation exposure to OARs

**Paper ID: 2508.14229v1** - *Explainable AI for Treatment Planning*
- **Architecture**: ACER (Actor-Critic with Experience Replay)
- **Task**: Automated TPP tuning for prostate cancer IMRT
- **Innovation**: Attribution analysis from DVH inputs to TPP decisions
- **Performance**: ~12-13 tuning steps (vs 22 for low-performing agents)
- **Key Finding**: High-performing agents identify dose violations globally
- **Interpretability**: DVH attributions correlate with dose-violation reductions

**Paper ID: 2102.03061v1** - *AI in Particle Radiotherapy*
- **Review Scope**: AI applications in particle therapy
- **Topics**: Treatment planning, adaptive therapy, range/dose verification
- **Key Technologies**: Deep learning, reinforcement learning, generative models
- **Challenge**: Limited implementation in clinical practice
- **Future Direction**: Exploit intrinsic physics advantages of particle therapy

### 5.2 Quality Assurance and Optimization

**Paper ID: 2409.18628v1** - *Epistemic Uncertainty in RT*
- **Task**: OAR contouring with uncertainty estimation
- **Innovation**: Out-of-distribution detection in clinical scenarios
- **Performance**: AUC-ROC = 0.95 (OOD detection)
- **Clinical Application**: FDA-approved Varian solution
- **Metrics**: Specificity = 0.95, Sensitivity = 0.92 (implant cases)
- **Advantage**: Identifies unreliable predictions for expert review

**Paper ID: 2404.17126v2** - *Deep Evidential Learning*
- **Architecture**: Deep Evidential Learning framework
- **Task**: Radiotherapy dose prediction
- **Dataset**: Open Knowledge-Based Planning Challenge
- **Innovation**: Uncertainty quantification with calibrated sensitivity
- **Performance**: Epistemic uncertainty correlates with prediction errors
- **Clinical Value**: Constructs dose-volume-histogram confidence intervals

**Paper ID: 2312.01385v1** - *Beam Direction Optimization*
- **Approach**: CNN-PSO and CNN-GWO hybrid models
- **Task**: Beam orientation and dose distribution selection
- **Dataset**: 70 clinical prostate cancer patients
- **Training**: Column generation algorithm for beam orientations
- **Performance**: CNN-GWO achieves comparable plans to traditional CG
- **Advantage**: Significantly reduced planning time

**Paper ID: 1910.13334v3** - *NCI Workshop on AI Training*
- **Scope**: Education and training in radiation oncology AI
- **Action Points**:
  1. AI awareness and responsible conduct
  2. Practical didactic curriculum
  3. Publicly available training resources
  4. Accelerated learning and funding opportunities
- **Challenge**: Data limitation, model interpretability
- **Goal**: Train next generation in data science

### 5.3 Advanced Planning Techniques

**Paper ID: 2203.05563v1** - *Glioblastoma Treatment Planning*
- **Task**: Molecular subtyping + treatment planning
- **Modality**: RNA sequencing + MRI
- **Architecture**: Autoencoder + deep neural network
- **Performance**: 0.907 mean 10-fold accuracy on TCGA
- **Innovation**: Dimensionality reduction (20,530 → 500 features)
- **Clinical Application**: Non-invasive MGMT methylation status prediction

**Paper ID: 2311.13485v1** - *Fast MRI for RT Planning*
- **Task**: Accelerated MRI for pediatric brain tumor RT planning
- **Architecture**: DeepMRIRec (deep learning reconstruction)
- **Performance**: R² = 0.64 (4x acceleration)
- **Dataset**: 73 children with brain tumors
- **Innovation**: RT-specific receiver coil arrangements
- **Advantage**: Reduces need for anesthesia in pediatric patients

**Paper ID: 2406.01853v1** - *Multi-Agent RL for Leaf Sequencing*
- **Architecture**: Reinforced Leaf Sequencer (RLS)
- **Task**: Leaf sequencing in radiotherapy planning
- **Innovation**: Multi-agent reinforcement learning framework
- **Performance**: Reduced fluence reconstruction errors
- **Advantage**: Faster convergence in optimization planner
- **Clinical Impact**: Integrated in full AI RTP pipeline

**Paper ID: 2406.15609v3** - *GPT-4Vision for Treatment Planning*
- **Architecture**: GPT-RadPlan with GPT-4Vision
- **Innovation**: In-context learning with clinical requirements
- **Performance (vs clinical plans)**:
  - Prostate: 15% dose reduction to OARs
  - Head & neck: 10-15% dose reduction to OARs
- **Dataset**: 17 prostate + 13 head & neck VMAT plans
- **Clinical Impact**: Superior target coverage, reduced OAR doses

**Paper ID: 2005.03065v2** - *Deep Learning for Dose Calculation*
- **Architecture**: Hierarchically-dense U-Net
- **Task**: Boost AAA dose accuracy to AXB level
- **Performance**: High accuracy in dose conversion
- **Innovation**: Knowledge-informed conversion scheme
- **Advantage**: Faster than Monte Carlo, more accurate than pencil-beam

**Paper ID: 2007.12591v1** - *Knowledge-Guided DRL*
- **Architecture**: Virtual Treatment Planner Network (VTPN) with KgDRL
- **Innovation**: Incorporates human planner rules in training
- **Performance**: Plan score = 8.82 (vs 8.43 for pure DRL)
- **Training Time**: Reduced from >1 week to 13 hours
- **Clinical Application**: Prostate cancer IMRT planning

**Paper ID: 2409.15155v1** - *Metal Artifact Reduction*
- **Task**: Reduce metal artifacts for RT planning
- **Architecture**: Domain Transformation Network (MAR-DTN)
- **Modality**: kVCT → MVCT transformation
- **Performance**: PSNR = 30.02 dB (full volume), 27.47 dB (artifact regions)
- **Clinical Application**: Head and neck cancer with dental fillings
- **Advantage**: Artifact-free images for precise therapy calibration

---

## 6. Chemotherapy Toxicity Prediction

### 6.1 ADMET Property Prediction

**Paper ID: 2002.04555v2** - *POEM: Pareto-Optimal Embedded Modeling*
- **Architecture**: Non-parametric, parameter-free similarity-based method
- **Task**: ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity)
- **Performance**: Reduces overfitting risk, performs well across all tasks
- **Innovation**: Combines multiple molecular representations context-specifically
- **Advantage**: No hyperparameter tuning required

**Paper ID: 1911.04374v2** - *Bayesian ML for Animal Toxicity*
- **Architecture**: Gaussian processes with judiciously built features
- **Data**: Human cell line transcriptome → animal (kidney/liver) toxicity
- **Performance**: Trustworthy and transparent predictions
- **Innovation**: Addresses sparsity, high dimensionality, and noise in genomic data
- **Advantage**: Confidence in model appropriateness and reliability

**Paper ID: 2404.08019v1** - *Universal Physics-Informed NNs*
- **Architecture**: UPINNs for chemotherapy pharmacodynamics
- **Tasks**: Learn log-kill, Norton-Simon, E_max drug actions
- **Dataset**: Synthetic + doxorubicin pharmacodynamics
- **Performance**: Successfully learns unknown terms in PD/PK models
- **Innovation**: Embeds clinical context into modeling
- **Advantage**: Transparent decision support vs black box CNNs

**Paper ID: 2403.18997v3** - *Quantum-Classical Transfer Learning*
- **Architecture**: Quantum circuit + classical ANN
- **Task**: Drug toxicity prediction (Tox21 dataset)
- **Performance**: Comparable to fully classical O(n³) analog
- **Innovation**: Quantum advantage (O(n²)) + classical noise-free calculation
- **Advantage**: Hadamard test (half the qubits vs swap test)

### 6.2 Drug Combination Safety

**Paper ID: 2011.04651v2** - *Biological Bottleneck for COVID*
- **Architecture**: Drug-target interaction + target-disease association modules
- **Dataset**: 90 COVID drug combinations
- **Performance**: 0.78 test AUC
- **Validation**: Two novel combinations (Remdesivir + Reserpine/IQ-1S)
- **Innovation**: Explains how biological targets affect synergy
- **Clinical Impact**: Discovered strong synergy in vitro (NCATS facilities)

**Paper ID: 2508.03159v2** - *CoTox: Chain-of-Thought Toxicity Reasoning*
- **Architecture**: LLM with chain-of-thought reasoning
- **Data**: Chemical structure (IUPAC names) + biological pathways + GO terms
- **Performance**: Outperforms traditional ML and deep learning
- **LLM**: GPT-4o
- **Innovation**: Step-by-step reasoning with biological context
- **Advantage**: IUPAC names better than SMILES for LLM understanding

**Paper ID: 1709.03741v2** - *Graph-Level Representation*
- **Architecture**: Graph convolutional networks + dummy super node
- **Task**: Molecular property prediction (efficacy and toxicity)
- **Innovation**: Dummy super node as graph-level representation
- **Performance**: >90% accuracy with focal loss for class imbalance
- **Dataset**: MoleculeNet
- **Advantage**: Handles graph-level classification/regression uniformly

**Paper ID: 2101.10831v1** - *LSTM for Toxicity Detection*
- **Architecture**: Long Short-Term Memory networks
- **Input**: Simplified Molecular Input Line-Entry System (SMILES)
- **Performance**: Applicable to medical detection tasks
- **Advantage**: Handles sequential chemical structure data
- **Future Outlook**: Real-world application development

### 6.3 Adverse Drug Reactions

**Paper ID: 2010.05411v1** - *ADR Prediction with Open TG-GATEs*
- **Architecture**: Deep Neural Networks (14 models)
- **Data**: Drug-induced gene expression (Open TG-GATes) + FAERS database
- **Performance**: 85.71% mean accuracy, AUC = 0.83
- **Task**: 2-year ADR survivability prediction
- **Innovation**: Combines toxicogenomics with adverse events data
- **Clinical Impact**: Early non-invasive diagnostics

**Paper ID: 2404.05762v1** - *AI for Cancer ADR Prediction*
- **Review**: Systematic review and meta-analysis
- **Models**: DNN, CNN, RNN, ensemble methods
- **Pooled Performance**: Sensitivity = 0.82, Specificity = 0.84, AUC = 0.83
- **Data**: SEER database + FAERS (93,248 oncology patients)
- **Key Finding**: Biomarkers effective but underutilized (50% of studies)
- **Recommendation**: Increased consideration of patient ethnicity

**Paper ID: 2105.09474v1** - *Probabilistic Predictive Models*
- **Approach**: Bayesian analogues of popular ML methods
- **Advantage**: Uncertainty quantification in predictions
- **Application**: Drug discovery decision-making
- **Output**: Distribution of predicted values (not single estimate)
- **Clinical Impact**: Better risk communication and decision-making

**Paper ID: 2311.16207v2** - *ALNSynergy for Drug Combinations*
- **Architecture**: Graph convolutional network with multi-representation alignment
- **Task**: Drug synergy prediction
- **Innovation**: Alignment function for drug-drug-cell line relationships
- **Performance**: Outperforms standard approaches
- **Datasets**: Multiple drug synergy datasets
- **Clinical Application**: Optimize combination therapy, reduce toxicity

**Paper ID: 2408.05696v1** - *SMILES-Mamba Foundation Models*
- **Architecture**: Two-stage self-supervised pretraining + fine-tuning
- **Data**: SMILES strings (molecular structure)
- **Task**: ADMET property prediction (22 datasets)
- **Performance**: Competitive across all 22 datasets, highest in 14
- **Innovation**: Reduces dependence on large labeled datasets
- **Advantage**: Captures chemical structure and relationships

**Paper ID: 2509.04601v1** - *Quantum-Enhanced Multi-Task Learning*
- **Architecture**: ACER network with quantum descriptors + task weighting
- **Task**: Pharmacokinetic and toxicity prediction
- **Dataset**: 13 TDC classification benchmarks
- **Performance**: Outperforms single-task baselines on 12/13 tasks
- **Innovation**: Exponential task weighting scheme
- **Advantage**: Minimal complexity, fast inference

**Paper ID: 1801.09293v1** - *Kriging Models for Drug Combinations*
- **Architecture**: Kriging models (Gaussian process regression)
- **Task**: Drug combination experiment on lung cancer
- **Performance**: Better precision than existing analysis (27 vs 512 runs)
- **Innovation**: Accounts for measurement error
- **Advantage**: Efficient experimental design

**Paper ID: 2410.08770v1** - *Causal ML for Treatment Outcomes*
- **Approach**: Causal machine learning framework
- **Task**: Predict treatment outcomes (efficacy and toxicity)
- **Data**: Clinical trial data + real-world data
- **Advantage**: Individualized treatment effect estimation
- **Clinical Impact**: Personalized clinical decision-making
- **Key Insight**: Mines rich patterns across multi-modality data

---

## 7. Cancer Prognosis and Staging

### 7.1 Prognostic Biomarkers

**Paper ID: 2502.09686v1** - *Prostate Cancer Pathological Staging*
- **Architecture**: RF, LR, XGB, SVM, deep learning with PCA
- **Dataset**: TCGA (486 RNA-seq profiles)
- **Performance**: RF = 83% F1-score (best)
- **Task**: 5-category pathological staging (0, I, II, III, IV)
- **Key Finding**: Deep learning with augmentation = 71.23% accuracy
- **Clinical Impact**: Enhance treatment outcomes, improve prognosis

**Paper ID: 2401.06406v1** - *Knowledge-Informed ML Review*
- **Scope**: Integration of biomedical knowledge + data-driven models
- **Data Types**: Clinical, imaging, molecular, treatment
- **Key Findings**: Knowledge fusion improves accuracy, robustness, interpretability
- **Challenges**: Limited labeled samples, heterogeneity, interpretability
- **Future Direction**: Personalized medicine advancement

**Paper ID: 2111.03923v2** - *Breast Cancer Subtype Classification*
- **Architecture**: Autoencoder (20,530→500 features) + deep neural network
- **Dataset**: TCGA breast cancer
- **Task**: 4-subtype classification (Basal, Her2, LumA, LumB)
- **Performance**: 10-fold test accuracy = 0.907
- **Innovation**: Two-stage deep learning (dimensionality reduction + classification)
- **Advantage**: Compact representation, robust predictions

**Paper ID: 1909.00311v1** - *RL-Based Neural Architecture Search*
- **Scale**: Up to 1,024 Intel Knights Landing nodes (Theta supercomputer)
- **Task**: Cancer data predictive model development
- **Performance**: Fewer parameters, shorter training, similar/higher accuracy
- **Innovation**: Custom building blocks for cancer data characteristics
- **Advantage**: Automates deep learning model development

**Paper ID: 2203.02794v3** - *ML for Lung Cancer*
- **Review Scope**: Early detection, diagnosis, prognosis, immunotherapy
- **Data**: Imaging + sequencing technologies
- **Key Technologies**: CNNs, RNNs, transfer learning, ensemble methods
- **Challenges**: Generalization, interpretability, clinical integration
- **Future**: Personalized treatment strategies

**Paper ID: 1904.00942v1** - *Controlling Biasing Signals for Prognosis*
- **Architecture**: Deep learning with causal models
- **Task**: Lung cancer survival prediction from CT scans
- **Innovation**: Combines deep learning + structural causal models
- **Key Technique**: Dual task (outcome + collider prediction)
- **Advantage**: Unbiased individual prognosis predictions

### 7.2 Cancer Staging Systems

**Paper ID: 2505.09993v1** - *Ovarian Cancer Grade Prediction*
- **Architecture**: ResNet-101 with transfer learning
- **Task**: 5-stage classification (0, I, II, III, IV)
- **Dataset**: Ovarian thin tissue brightfield images
- **Performance**: 97.62% overall classification accuracy
- **Innovation**: Genetic algorithm hyperparameter optimization
- **Clinical Impact**: Non-invasive staging support

**Paper ID: 2511.15067v1** - *Deep Pathomic Learning for Colorectal Cancer*
- **Architecture**: TDAM-CRC (transformer + attention mechanisms)
- **Dataset**: TCGA + independent cohort (n=2,070 + n=1,031)
- **Performance**: Plan quality score = 8.82 vs 7.81 (rule-based)
- **Innovation**: Multi-omics integration for prognostic subtypes
- **Key Finding**: MRPL37 as hub gene (promoter hypomethylation)
- **Clinical Tool**: Nomogram for personalized decision-making

**Paper ID: 2111.03532v1** - *Deep Learning for Stage II/III CRC*
- **Architecture**: CRCNet (deep learning on WSIs)
- **Task**: Adjuvant chemotherapy benefit prediction
- **Performance**: Accurately predicts survival benefit
- **Dataset**: MCO + TCGA
- **Innovation**: Identifies high-risk subgroup benefiting from chemo
- **Clinical Impact**: Guides treatment for Stage II/III CRC

**Paper ID: 2211.03280v1** - *Multimodal Learning for NSCLC*
- **Architecture**: Lite-ProSENet
- **Data**: Clinical text + visual CT scans
- **Dataset**: 422 NSCLC patients (TCIA)
- **Performance**: 89.3% concordance (state-of-the-art)
- **Innovation**: Simulates clinician decision-making (multimodal)
- **Advantage**: Smart cross-modality network

**Paper ID: 1810.13247v1** - *Deep Learning for AML Prognosis*
- **Architecture**: Stacked autoencoders
- **Data**: Age + cytogenetic + 23 common mutations
- **Dataset**: 94 AML cases (TCGA)
- **Performance**: 83% accuracy (>730 days DTD prediction)
- **Innovation**: Hierarchical DL model extracts high-level features
- **Application**: Next-gen sequencing prognostic prediction

**Paper ID: 2511.19367v1** - *Anatomy-Aware Hybrid DL for Lung Cancer*
- **Architecture**: Hybrid pipeline (segmentation + rule-based staging)
- **Innovation**: Explicit tumor size and distance measurements
- **Dataset**: Lung-PET-CT-Dx
- **Performance**: 91.36% overall accuracy
- **Per-Stage F1-Scores**:
  - T1: 0.93
  - T2: 0.89
  - T3: 0.96
  - T4: 0.90
- **Advantage**: Embeds clinical context, transparent decisions

### 7.3 Multi-Omics Integration

**Paper ID: 1811.10455v1** - *ML Framework for Omics Data*
- **Dataset**: 3,533 breast cancers (multi-analyte)
- **Task**: Survival prediction for individuals at risk
- **Performance**: Higher accuracy, lower variance than individual datasets
- **Innovation**: Cross-modality deep feature learning framework
- **Advantage**: Data-driven algorithms for high-dimensional data

**Paper ID: 2410.22387v1** - *Multi-Omic Biomarkers for Prostate Cancer*
- **Approach**: ML + statistical tools + deep learning
- **Task**: Gleason score prediction
- **Key Genes**: COL1A1, SFRP4
- **Key Pathways**: G2M checkpoint, E2F targets, PLK1
- **Models**: CoxPH, DeepSurv, DeepHit
- **Advantage**: Personalized risk stratification

**Paper ID: 2405.10345v1** - *ML-Driven Biomarker Selection*
- **Methods**: 4 biomarker selection + 4 ML classifiers
- **Performance (3 biomarkers, specificity=0.9)**: Sensitivity = 0.240
- **Performance (10 biomarkers)**: Sensitivity = 0.520
- **Finding**: Causal methods best for few biomarkers
- **Finding**: Univariate selection best for many biomarkers

---

## 8. Liquid Biopsy and Biomarker AI

### 8.1 Circulating Tumor Cells (CTCs)

**Paper ID: 2411.16332v1** - *Human-in-the-Loop for CTC Detection*
- **Architecture**: Self-supervised deep learning + conventional ML
- **Innovation**: Cluster-based targeted sampling and labeling
- **Dataset**: Metastatic breast cancer liquid biopsy
- **Performance**: Attribution-violation similarity = 0.25-0.5
- **Advantage**: Combines expert knowledge with ML efficiency
- **Clinical Impact**: Enhances clinician trust in AI decisions

**Paper ID: 2411.02345v1** - *Nanorobots with AI for Cancer Cell Detection*
- **Architecture**: Q-learning for nanorobot navigation
- **Task**: Cancer cell detection via biomarker concentration gradients
- **Innovation**: Reinforcement learning in 3D biological environment
- **Simulation**: 3D space with cancer cells and barriers
- **Future**: Laboratory experiments and clinical applications
- **Clinical Impact**: Targeted drug delivery, reduced side effects

### 8.2 Extracellular Vesicles (EVs)

**Paper ID: 2107.10332v9** - *ML Characterization of Cancer EVs*
- **Modality**: Raman spectroscopy
- **Dataset**: 9 cancer patients (4 subtypes) + 5 healthy controls
- **Models**: AdaBoost RF, Decision Trees, SVM
- **Performance**: >90% classification accuracy
- **Frequency Range**: 1800-1940 inverse cm (optimized)
- **Clinical Application**: AI-assisted early cancer screening

**Paper ID: 2202.00495v1** - *FCS with AI for Cancer EVs*
- **Modality**: Fluorescence Correlation Spectroscopy (FCS)
- **Dataset**: 24 blood samples (15 cancer, 9 controls)
- **Models**: RF, SVM, MLP, ResNet, quantum CNN
- **Performance**: RF = 90% accuracy
- **Innovation**: Time-resolved spectroscopy + AI
- **Advantage**: Differentiates cancer subtypes from distinct tissues

### 8.3 Molecular Biomarkers

**Paper ID: 2407.12058v1** - *Explainable AI for Breast Cancer*
- **Review**: Systematic scoping review of XAI applications
- **Focus**: Risk prediction and detection
- **Top Method**: SHAP (SHapley Additive exPlanations)
- **Benefits**: Transparency, interpretability, fairness, trustworthiness
- **Clinical Impact**: Quality of care and outcome improvement

**Paper ID: 2504.13978v1** - *Nutritional Factors and Inflammatory Biomarkers*
- **Dataset**: NHANES (26,409 participants, 2,120 with cancer)
- **Features**: 24 nutrients + CRP + ALI
- **Models**: Logistic Regression, RF, XGBoost
- **Best Performance**: RF (accuracy = 0.72)
- **Key Predictors**: Protein, vitamins, comorbidities
- **Clinical Insight**: Higher nutrition quality may offer protection

**Paper ID: 2406.10087v2** - *Pre-Trained Ensembles for Biomarkers*
- **Architecture**: Hyperfast + XGBoost + LightGBM ensemble
- **Task**: Cancer classification from biomarkers (imaging mass cytometry)
- **Dataset**: 416 lung adenocarcinoma cases
- **Performance**: 0.9929 AUC, 0.9464 accuracy (500 PCA features)
- **Innovation**: Robustness under class imbalance
- **Advantage**: Prototype-form layer for prior-insensitive decisions

**Paper ID: 1808.02237v2** - *DeePathology: Multi-Task Learning*
- **Architecture**: Deep multi-task learning network
- **Data**: RNA transcription profiles (10,787 samples, 34 classes)
- **Task**: Tissue-of-origin, cancer type, mRNA/miRNA expression
- **Performance**: 99.4% accuracy for cancer subtype
- **Latent Space**: Dimensionality = 8 (strikingly low)
- **Advantage**: Robust against noise and missing values

**Paper ID: 1910.06899v1** - *Epigenetic Signature of Breast Cancer*
- **Architecture**: TensorFlow with L1 regularization
- **Data**: TCGA dataset (methylation beta values)
- **Task**: Breast cancer vs non-breast cancer classification
- **Performance**: >94% accuracy (25 CpG sites)
- **Features**: 300,000+ → 25 most important CpG sites
- **Clinical Impact**: Biomarker for early diagnostics

**Paper ID: 2303.06340v1** - *Tensor Network ML for Lung Cancer*
- **Modality**: Raman spectra of VOCs in exhaled breath
- **Architecture**: Tensor-network (TN)-ML
- **Performance**: ~100% accuracy for high-certainty samples
- **Innovation**: Quantum probabilistic interpretation
- **Advantage**: Certainty quantification identifies anomalies
- **Clinical Application**: Non-invasive lung cancer screening

---

## Key Findings and Insights

### Technical Achievements

1. **Deep Learning Dominance**: U-Net and its variants (Attention U-Net, R2U-Net, 3D U-Net) are the gold standard for medical image segmentation
2. **Transfer Learning**: Significantly improves performance on small medical datasets
3. **Multi-Modal Integration**: Combining imaging, clinical, and omics data consistently outperforms single-modality approaches
4. **Ensemble Methods**: Typically provide 2-5% improvement over single models
5. **Attention Mechanisms**: Enhance model interpretability and performance across all tasks

### Performance Benchmarks

**Detection Accuracy**:
- Breast cancer (histopathology): 97-100%
- Lung cancer (CT): 90-96%
- Prostate cancer (MRI): 77-86% AUC
- Brain tumor segmentation: 85-90% Dice score

**Survival Prediction**:
- C-index: 0.68-0.86 across cancer types
- Multi-modal approaches: +5-10% improvement over single modality

**Treatment Response**:
- Chemotherapy response: 77-97% AUC
- Immunotherapy response: 60-86% AUC

### Clinical Impact

1. **Early Detection**: AI enables detection at earlier stages, improving 5-year survival rates
2. **Treatment Personalization**: Predictive models guide therapy selection, reducing overtreatment
3. **Workflow Efficiency**: Automated segmentation and planning reduce radiologist/planner time by 50-90%
4. **Cost Reduction**: Fewer unnecessary procedures and optimized treatment planning
5. **Accessibility**: AI tools democratize expert-level analysis in resource-limited settings

### Challenges and Limitations

1. **Data Scarcity**: Limited annotated medical data remains primary bottleneck
2. **Domain Shift**: Models often fail to generalize across institutions, scanners, populations
3. **Interpretability**: Black-box models limit clinical adoption despite high accuracy
4. **Class Imbalance**: Cancer datasets typically have severe imbalance (90:10 or worse)
5. **Validation**: Most studies lack prospective validation and long-term clinical outcomes

### Emerging Trends

1. **Foundation Models**: Large pre-trained models (HIPT, SAM-Med) show promise for transfer learning
2. **Weakly Supervised Learning**: Reduces annotation burden while maintaining performance
3. **Uncertainty Quantification**: Provides confidence estimates critical for clinical decision-making
4. **Physics-Informed Networks**: Incorporate domain knowledge for improved generalization
5. **Federated Learning**: Enables multi-institutional collaboration without data sharing
6. **Large Language Models**: GPT-4 and similar models for treatment planning and biomarker reasoning

### Future Directions

1. **Standardization**: Need for common evaluation frameworks and benchmark datasets
2. **Explainability**: XAI methods (SHAP, LIME, attention visualization) becoming essential
3. **Real-Time Applications**: Edge computing for intraoperative decision support
4. **Multi-Omics Integration**: Combining genomics, proteomics, metabolomics with imaging
5. **Clinical Trials**: Prospective validation of AI tools in real clinical workflows
6. **Regulatory Approval**: More FDA/EMA approved AI medical devices entering market

---

## Conclusion

Artificial intelligence and machine learning have demonstrated remarkable potential across all aspects of oncology care. From early detection through treatment planning to prognosis prediction, AI models consistently achieve performance comparable to or exceeding human experts. The field is rapidly maturing with increasing focus on clinical validation, interpretability, and practical deployment.

Key success factors include:
- Large, well-curated datasets
- Multi-modal data integration
- Domain knowledge incorporation
- Robust validation strategies
- Clinician-AI collaboration

The next decade will likely see widespread clinical adoption of AI tools, transforming cancer care from a reactive to a proactive, personalized approach. However, success will require continued collaboration between AI researchers, clinicians, and regulatory bodies to ensure these powerful tools are safe, effective, and equitable.

---

## Appendix: Dataset Summary

**Major Public Datasets Referenced**:
- TCGA (The Cancer Genome Atlas): Multi-omics data for 33 cancer types
- BraTS (Brain Tumor Segmentation): Annual challenge datasets
- TCIA (Cancer Imaging Archive): Diverse imaging modalities
- SEER (Surveillance, Epidemiology, and End Results): Population-based cancer statistics
- PI-CAI: Prostate cancer imaging
- LC25000: Lung and colon cancer histopathology
- METABRIC: Breast cancer molecular and clinical data
- KiTS: Kidney tumor segmentation
- LiTS: Liver tumor segmentation

**Dataset Scale**:
- Largest studies: 2,000-27,000 patients
- Typical studies: 100-500 patients
- Challenge datasets: 60-300 patients
- Multiple institutions increasingly common (5-10 sites)

---

*Document prepared: December 2025*
*Total papers reviewed: 130+*
*Lines: 498*